| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Venous Thrombosis | 11 | 2012 | 98 | 1.300 |
Why?
|
| Glycoproteins | 23 | 2003 | 123 | 1.140 |
Why?
|
| Protein C | 25 | 2015 | 38 | 1.010 |
Why?
|
| Warfarin | 13 | 2005 | 94 | 0.770 |
Why?
|
| Thromboembolism | 7 | 2007 | 57 | 0.760 |
Why?
|
| Anticoagulants | 16 | 2008 | 295 | 0.720 |
Why?
|
| Thrombophlebitis | 9 | 2006 | 51 | 0.590 |
Why?
|
| Contraceptives, Oral | 6 | 2006 | 23 | 0.530 |
Why?
|
| Thrombosis | 14 | 2002 | 150 | 0.480 |
Why?
|
| Postoperative Complications | 6 | 2005 | 631 | 0.470 |
Why?
|
| Factor VIIa | 5 | 2006 | 29 | 0.450 |
Why?
|
| Blood Coagulation Factors | 7 | 2006 | 31 | 0.440 |
Why?
|
| Protein S | 18 | 2001 | 26 | 0.440 |
Why?
|
| Receptors, Cell Surface | 9 | 2003 | 114 | 0.430 |
Why?
|
| Prothrombin | 5 | 2006 | 15 | 0.410 |
Why?
|
| Arthroplasty, Replacement, Knee | 5 | 2008 | 38 | 0.390 |
Why?
|
| Fibrinolytic Agents | 4 | 2005 | 70 | 0.390 |
Why?
|
| Blood Coagulation | 13 | 1995 | 120 | 0.390 |
Why?
|
| Protein C Deficiency | 7 | 2002 | 7 | 0.380 |
Why?
|
| Arthroplasty, Replacement, Hip | 3 | 2005 | 29 | 0.370 |
Why?
|
| Humans | 77 | 2017 | 28581 | 0.360 |
Why?
|
| Glycogen Storage Disease Type VII | 1 | 2011 | 2 | 0.350 |
Why?
|
| Mesenteric Veins | 1 | 2011 | 3 | 0.350 |
Why?
|
| Portal Vein | 1 | 2011 | 8 | 0.350 |
Why?
|
| Blood Platelets | 7 | 1998 | 206 | 0.350 |
Why?
|
| Blood Coagulation Tests | 6 | 2006 | 27 | 0.340 |
Why?
|
| Coronary Disease | 4 | 2001 | 120 | 0.310 |
Why?
|
| Thrombomodulin | 3 | 2005 | 11 | 0.300 |
Why?
|
| Point Mutation | 2 | 2006 | 60 | 0.290 |
Why?
|
| Risk Factors | 13 | 2008 | 2111 | 0.270 |
Why?
|
| Nucleic Acid Denaturation | 1 | 2006 | 4 | 0.260 |
Why?
|
| Middle Aged | 31 | 2017 | 7310 | 0.250 |
Why?
|
| Enoxaparin | 2 | 2008 | 38 | 0.240 |
Why?
|
| Female | 39 | 2015 | 15471 | 0.240 |
Why?
|
| Temperature | 1 | 2006 | 213 | 0.240 |
Why?
|
| Genetic Variation | 2 | 2006 | 245 | 0.240 |
Why?
|
| Male | 34 | 2017 | 13771 | 0.220 |
Why?
|
| Coronary Artery Disease | 2 | 1997 | 218 | 0.220 |
Why?
|
| Adult | 24 | 2012 | 7922 | 0.210 |
Why?
|
| Complement Inactivator Proteins | 3 | 1990 | 8 | 0.210 |
Why?
|
| Thrombin | 10 | 2008 | 69 | 0.210 |
Why?
|
| Fibrinogen | 6 | 1996 | 50 | 0.210 |
Why?
|
| Orthopedic Procedures | 1 | 2003 | 27 | 0.200 |
Why?
|
| Aged | 23 | 2015 | 5525 | 0.200 |
Why?
|
| Antibodies, Monoclonal | 5 | 2012 | 333 | 0.190 |
Why?
|
| Factor Xa Inhibitors | 1 | 2003 | 55 | 0.190 |
Why?
|
| Heparin | 7 | 2003 | 111 | 0.190 |
Why?
|
| Thromboplastin | 4 | 2006 | 28 | 0.180 |
Why?
|
| Factor V | 7 | 2006 | 14 | 0.170 |
Why?
|
| Skin | 2 | 1993 | 151 | 0.170 |
Why?
|
| Disseminated Intravascular Coagulation | 4 | 2004 | 16 | 0.160 |
Why?
|
| Venous Thromboembolism | 2 | 2015 | 134 | 0.160 |
Why?
|
| Prospective Studies | 8 | 2015 | 1272 | 0.160 |
Why?
|
| Coronary Angiography | 2 | 1997 | 150 | 0.150 |
Why?
|
| Blood Coagulation Disorders | 4 | 2004 | 28 | 0.150 |
Why?
|
| Embolism | 2 | 1999 | 14 | 0.150 |
Why?
|
| Dermatan Sulfate | 1 | 1998 | 3 | 0.150 |
Why?
|
| Heparitin Sulfate | 1 | 1998 | 14 | 0.150 |
Why?
|
| Platelet Function Tests | 2 | 1998 | 24 | 0.150 |
Why?
|
| Liver Diseases | 3 | 1988 | 52 | 0.150 |
Why?
|
| Chondroitin Sulfates | 1 | 1998 | 23 | 0.140 |
Why?
|
| Aspirin | 3 | 1998 | 125 | 0.140 |
Why?
|
| Neoplasms | 3 | 2017 | 857 | 0.140 |
Why?
|
| Fibrinolysis | 7 | 2004 | 21 | 0.130 |
Why?
|
| Blood Loss, Surgical | 2 | 1998 | 53 | 0.130 |
Why?
|
| Laboratories | 1 | 1996 | 18 | 0.130 |
Why?
|
| Specimen Handling | 1 | 1996 | 33 | 0.130 |
Why?
|
| Protein S Deficiency | 3 | 2006 | 5 | 0.120 |
Why?
|
| Factor VIII | 2 | 2015 | 19 | 0.120 |
Why?
|
| Pregnancy | 6 | 1997 | 1219 | 0.120 |
Why?
|
| Prothrombin Time | 3 | 2006 | 21 | 0.120 |
Why?
|
| Factor VII | 3 | 2006 | 3 | 0.120 |
Why?
|
| Endothelium, Vascular | 3 | 2003 | 328 | 0.120 |
Why?
|
| Disease Progression | 1 | 2017 | 475 | 0.120 |
Why?
|
| Polysaccharides | 2 | 2007 | 63 | 0.110 |
Why?
|
| Azetidines | 2 | 2005 | 6 | 0.110 |
Why?
|
| Ventricular Dysfunction | 1 | 1994 | 7 | 0.110 |
Why?
|
| Aged, 80 and over | 8 | 2012 | 2045 | 0.110 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 2 | 2012 | 10 | 0.110 |
Why?
|
| Thrombolytic Therapy | 1 | 1994 | 39 | 0.110 |
Why?
|
| Double-Blind Method | 6 | 2008 | 421 | 0.110 |
Why?
|
| Antithrombin III Deficiency | 3 | 1992 | 6 | 0.110 |
Why?
|
| Lymphopoiesis | 2 | 2005 | 22 | 0.100 |
Why?
|
| Recombinant Proteins | 5 | 2005 | 415 | 0.100 |
Why?
|
| Carrier Proteins | 3 | 1990 | 252 | 0.100 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 1993 | 9 | 0.100 |
Why?
|
| Hemostasis | 3 | 1998 | 48 | 0.100 |
Why?
|
| Coumarins | 1 | 1993 | 5 | 0.100 |
Why?
|
| Contraception | 1 | 1993 | 29 | 0.100 |
Why?
|
| Drug Eruptions | 1 | 1993 | 7 | 0.100 |
Why?
|
| Lymphocytes | 2 | 2005 | 90 | 0.100 |
Why?
|
| Receptors, Thrombin | 7 | 1991 | 9 | 0.100 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 100 | 0.090 |
Why?
|
| Cyclosporins | 1 | 1991 | 2 | 0.090 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2012 | 107 | 0.090 |
Why?
|
| Protein Deficiency | 1 | 1990 | 4 | 0.090 |
Why?
|
| Treatment Outcome | 7 | 2007 | 2402 | 0.090 |
Why?
|
| Antithrombin III | 2 | 1992 | 6 | 0.090 |
Why?
|
| Abdomen | 2 | 2007 | 41 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2006 | 328 | 0.080 |
Why?
|
| Blood Proteins | 4 | 1986 | 68 | 0.080 |
Why?
|
| Surgical Procedures, Operative | 2 | 2007 | 49 | 0.080 |
Why?
|
| Lupus Coagulation Inhibitor | 2 | 2000 | 11 | 0.080 |
Why?
|
| Animals | 16 | 2005 | 10580 | 0.080 |
Why?
|
| Administration, Oral | 3 | 2008 | 190 | 0.080 |
Why?
|
| Pedigree | 6 | 1991 | 155 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 478 | 0.070 |
Why?
|
| Benzimidazoles | 1 | 2008 | 32 | 0.070 |
Why?
|
| Logistic Models | 3 | 2001 | 409 | 0.070 |
Why?
|
| Intermittent Pneumatic Compression Devices | 1 | 2007 | 1 | 0.070 |
Why?
|
| Pyridines | 1 | 2008 | 108 | 0.070 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2005 | 128 | 0.070 |
Why?
|
| Radial Artery | 1 | 2007 | 21 | 0.070 |
Why?
|
| DNA Probes | 1 | 2006 | 13 | 0.060 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2006 | 77 | 0.060 |
Why?
|
| Heterozygote | 1 | 2006 | 69 | 0.060 |
Why?
|
| Activated Protein C Resistance | 1 | 2006 | 2 | 0.060 |
Why?
|
| Metabolic Syndrome | 1 | 2007 | 80 | 0.060 |
Why?
|
| Cattle | 5 | 1991 | 388 | 0.060 |
Why?
|
| Pulmonary Embolism | 3 | 2005 | 126 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 1 | 2006 | 376 | 0.060 |
Why?
|
| Immunoelectrophoresis, Two-Dimensional | 3 | 1990 | 3 | 0.060 |
Why?
|
| Pilot Projects | 3 | 1995 | 458 | 0.060 |
Why?
|
| Dexamethasone | 1 | 2005 | 63 | 0.060 |
Why?
|
| Factor X | 5 | 2006 | 11 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2012 | 893 | 0.060 |
Why?
|
| Glucocorticoids | 1 | 2005 | 115 | 0.050 |
Why?
|
| Extracorporeal Circulation | 2 | 1995 | 3 | 0.050 |
Why?
|
| Hypercholesterolemia | 2 | 1995 | 18 | 0.050 |
Why?
|
| Clinical Trials as Topic | 2 | 1996 | 216 | 0.050 |
Why?
|
| Cholesterol, LDL | 2 | 1995 | 64 | 0.050 |
Why?
|
| gamma-Tocopherol | 1 | 2004 | 1 | 0.050 |
Why?
|
| Stem Cells | 1 | 2005 | 122 | 0.050 |
Why?
|
| Antithrombins | 1 | 1984 | 28 | 0.050 |
Why?
|
| Endothelins | 1 | 2003 | 7 | 0.050 |
Why?
|
| Chromans | 1 | 2004 | 59 | 0.050 |
Why?
|
| Postphlebitic Syndrome | 1 | 2003 | 1 | 0.050 |
Why?
|
| Surgical Wound Infection | 1 | 2004 | 107 | 0.050 |
Why?
|
| Sepsis | 1 | 2004 | 86 | 0.050 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2003 | 35 | 0.050 |
Why?
|
| Immunosorbent Techniques | 4 | 1988 | 12 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2003 | 102 | 0.050 |
Why?
|
| Recurrence | 3 | 1992 | 325 | 0.050 |
Why?
|
| Thrombophilia | 1 | 2002 | 10 | 0.050 |
Why?
|
| Acute Disease | 1 | 2003 | 155 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 1986 | 671 | 0.050 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2002 | 12 | 0.050 |
Why?
|
| Tetrazoles | 1 | 2002 | 9 | 0.050 |
Why?
|
| Age Factors | 3 | 2002 | 734 | 0.050 |
Why?
|
| Patient Education as Topic | 1 | 2003 | 91 | 0.050 |
Why?
|
| Partial Thromboplastin Time | 2 | 2004 | 18 | 0.050 |
Why?
|
| Mutation | 1 | 2006 | 864 | 0.050 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2001 | 2 | 0.050 |
Why?
|
| Vasodilator Agents | 1 | 2002 | 79 | 0.050 |
Why?
|
| Bleeding Time | 3 | 1998 | 3 | 0.050 |
Why?
|
| Receptors, Estrogen | 1 | 2001 | 43 | 0.050 |
Why?
|
| Hematopoiesis | 1 | 2001 | 25 | 0.050 |
Why?
|
| Necrosis | 2 | 1993 | 85 | 0.040 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2001 | 30 | 0.040 |
Why?
|
| Helminth Proteins | 1 | 2001 | 19 | 0.040 |
Why?
|
| Protein C Inhibitor | 3 | 1986 | 5 | 0.040 |
Why?
|
| Immunoglobulin Fab Fragments | 2 | 2012 | 21 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2002 | 244 | 0.040 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 1994 | 191 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2001 | 68 | 0.040 |
Why?
|
| Immunoassay | 1 | 2001 | 36 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2005 | 257 | 0.040 |
Why?
|
| Time Factors | 6 | 2005 | 1600 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2001 | 83 | 0.040 |
Why?
|
| Smoking | 2 | 1996 | 476 | 0.040 |
Why?
|
| Intermittent Claudication | 1 | 2002 | 117 | 0.040 |
Why?
|
| Biomarkers | 1 | 2004 | 770 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2002 | 285 | 0.040 |
Why?
|
| Popliteal Vein | 1 | 2000 | 3 | 0.040 |
Why?
|
| Sensitivity and Specificity | 3 | 2012 | 524 | 0.040 |
Why?
|
| Femoral Vein | 1 | 2000 | 13 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2001 | 391 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2001 | 125 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2008 | 611 | 0.040 |
Why?
|
| Enzyme Activation | 3 | 1986 | 267 | 0.040 |
Why?
|
| Iliac Artery | 1 | 1999 | 19 | 0.040 |
Why?
|
| Antibodies | 1 | 2000 | 124 | 0.040 |
Why?
|
| Lipids | 1 | 2001 | 214 | 0.040 |
Why?
|
| Aortic Diseases | 1 | 1999 | 17 | 0.040 |
Why?
|
| Hyperhomocysteinemia | 1 | 1999 | 28 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2001 | 426 | 0.040 |
Why?
|
| Streptokinase | 1 | 1979 | 5 | 0.040 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1999 | 44 | 0.040 |
Why?
|
| Incidence | 1 | 2001 | 568 | 0.040 |
Why?
|
| Femoral Artery | 1 | 1999 | 58 | 0.040 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 1999 | 27 | 0.040 |
Why?
|
| Plasminogen Activators | 3 | 1984 | 7 | 0.040 |
Why?
|
| Cell Lineage | 3 | 2005 | 51 | 0.040 |
Why?
|
| Estrogen Replacement Therapy | 1 | 1999 | 43 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 1998 | 46 | 0.040 |
Why?
|
| Platelet Activation | 2 | 2015 | 54 | 0.040 |
Why?
|
| Radioimmunoassay | 2 | 1990 | 45 | 0.040 |
Why?
|
| Drug Combinations | 1 | 1998 | 50 | 0.040 |
Why?
|
| Platelet Aggregation | 3 | 1998 | 44 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2015 | 226 | 0.040 |
Why?
|
| Blood Platelet Disorders | 1 | 1998 | 10 | 0.040 |
Why?
|
| Phlebography | 3 | 2005 | 20 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 1995 | 208 | 0.030 |
Why?
|
| Diabetes Mellitus | 2 | 1996 | 215 | 0.030 |
Why?
|
| Hemorrhage | 3 | 2005 | 265 | 0.030 |
Why?
|
| Protein Binding | 3 | 1996 | 664 | 0.030 |
Why?
|
| Immunoelectrophoresis | 2 | 1987 | 3 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 1996 | 24 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2017 | 130 | 0.030 |
Why?
|
| Reference Values | 2 | 1987 | 199 | 0.030 |
Why?
|
| Complement C4 | 2 | 1986 | 16 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 1996 | 145 | 0.030 |
Why?
|
| Placebos | 2 | 2007 | 48 | 0.030 |
Why?
|
| Kinetics | 2 | 1991 | 551 | 0.030 |
Why?
|
| Thrombopoietin | 1 | 1996 | 17 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2005 | 1009 | 0.030 |
Why?
|
| Blood Component Removal | 1 | 1995 | 4 | 0.030 |
Why?
|
| Dogs | 3 | 1996 | 510 | 0.030 |
Why?
|
| Injections, Subcutaneous | 2 | 2008 | 60 | 0.030 |
Why?
|
| Vitamin K | 2 | 1986 | 39 | 0.030 |
Why?
|
| Cardiovascular Diseases | 2 | 2004 | 373 | 0.030 |
Why?
|
| Mice | 5 | 2005 | 4732 | 0.030 |
Why?
|
| Lipoproteins, LDL | 1 | 1995 | 36 | 0.030 |
Why?
|
| Europe | 2 | 2008 | 99 | 0.030 |
Why?
|
| Phosphatidylethanolamines | 1 | 1995 | 26 | 0.030 |
Why?
|
| Benzylamines | 2 | 2005 | 19 | 0.030 |
Why?
|
| Adolescent | 4 | 1998 | 3165 | 0.030 |
Why?
|
| Phospholipids | 1 | 1995 | 76 | 0.030 |
Why?
|
| Heart Aneurysm | 1 | 1994 | 10 | 0.030 |
Why?
|
| Drug Administration Schedule | 3 | 2003 | 224 | 0.030 |
Why?
|
| Sex Factors | 1 | 1996 | 467 | 0.030 |
Why?
|
| ROC Curve | 1 | 1995 | 144 | 0.030 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 1994 | 19 | 0.030 |
Why?
|
| Heart Neoplasms | 1 | 1994 | 17 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 1996 | 194 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 1996 | 732 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2012 | 782 | 0.030 |
Why?
|
| Fetal Blood | 3 | 2002 | 40 | 0.030 |
Why?
|
| Factor Xa | 2 | 1984 | 15 | 0.030 |
Why?
|
| Bone Marrow Cells | 2 | 2005 | 81 | 0.030 |
Why?
|
| Mice, Inbred NOD | 2 | 2005 | 50 | 0.030 |
Why?
|
| Antigens, CD | 2 | 2005 | 140 | 0.030 |
Why?
|
| Plasmapheresis | 1 | 1993 | 6 | 0.030 |
Why?
|
| Autoanalysis | 1 | 1993 | 1 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 1987 | 899 | 0.030 |
Why?
|
| Plasminogen | 2 | 1986 | 8 | 0.020 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 1992 | 15 | 0.020 |
Why?
|
| Isotope Labeling | 1 | 2012 | 31 | 0.020 |
Why?
|
| Skin Transplantation | 1 | 1992 | 15 | 0.020 |
Why?
|
| Mice, SCID | 2 | 2002 | 60 | 0.020 |
Why?
|
| Transplantation, Heterologous | 2 | 2002 | 60 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 1993 | 172 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2012 | 73 | 0.020 |
Why?
|
| Autoantibodies | 1 | 1995 | 479 | 0.020 |
Why?
|
| Isoflurophate | 2 | 1982 | 2 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 1994 | 351 | 0.020 |
Why?
|
| Hypobetalipoproteinemias | 1 | 1991 | 2 | 0.020 |
Why?
|
| Afibrinogenemia | 1 | 1991 | 3 | 0.020 |
Why?
|
| Swine | 1 | 1992 | 238 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 1991 | 15 | 0.020 |
Why?
|
| Exons | 1 | 1991 | 42 | 0.020 |
Why?
|
| Cell Differentiation | 2 | 2005 | 419 | 0.020 |
Why?
|
| Renal Artery | 1 | 1991 | 15 | 0.020 |
Why?
|
| Models, Cardiovascular | 1 | 1991 | 47 | 0.020 |
Why?
|
| Family Health | 1 | 1990 | 71 | 0.020 |
Why?
|
| Aorta | 1 | 1991 | 124 | 0.020 |
Why?
|
| Molecular Weight | 1 | 1990 | 122 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 1990 | 242 | 0.020 |
Why?
|
| Iodine Radioisotopes | 2 | 1979 | 36 | 0.020 |
Why?
|
| Phosphorylation | 1 | 1990 | 581 | 0.020 |
Why?
|
| Binding Sites | 2 | 1979 | 354 | 0.020 |
Why?
|
| Half-Life | 1 | 1988 | 34 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2005 | 1601 | 0.020 |
Why?
|
| North America | 1 | 2008 | 41 | 0.020 |
Why?
|
| Dabigatran | 1 | 2008 | 20 | 0.020 |
Why?
|
| Ultrasonography | 2 | 2000 | 241 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2000 | 480 | 0.020 |
Why?
|
| Nephrotic Syndrome | 1 | 1987 | 8 | 0.020 |
Why?
|
| Blood Pressure Determination | 1 | 2007 | 27 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2007 | 66 | 0.020 |
Why?
|
| Elasticity | 1 | 2007 | 54 | 0.020 |
Why?
|
| Indicators and Reagents | 1 | 2006 | 26 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2007 | 210 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 1990 | 485 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2006 | 36 | 0.020 |
Why?
|
| Base Sequence | 2 | 2001 | 588 | 0.020 |
Why?
|
| Leukemia | 1 | 1986 | 30 | 0.020 |
Why?
|
| Complement C4b | 1 | 1986 | 4 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 1986 | 74 | 0.010 |
Why?
|
| Bandages | 1 | 2005 | 14 | 0.010 |
Why?
|
| Genes, bcl-2 | 1 | 2005 | 3 | 0.010 |
Why?
|
| Mifepristone | 1 | 2005 | 4 | 0.010 |
Why?
|
| Hormone Antagonists | 1 | 2005 | 6 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2007 | 405 | 0.010 |
Why?
|
| Whole Blood Coagulation Time | 1 | 1984 | 6 | 0.010 |
Why?
|
| Models, Biological | 2 | 1984 | 468 | 0.010 |
Why?
|
| Hemoglobins | 1 | 2005 | 118 | 0.010 |
Why?
|
| APACHE | 1 | 2004 | 4 | 0.010 |
Why?
|
| Endothelium | 1 | 2004 | 28 | 0.010 |
Why?
|
| Fibrin | 1 | 2004 | 17 | 0.010 |
Why?
|
| Therapeutic Equivalency | 1 | 1984 | 4 | 0.010 |
Why?
|
| Goats | 1 | 1984 | 11 | 0.010 |
Why?
|
| Hypertension | 1 | 2007 | 309 | 0.010 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2004 | 6 | 0.010 |
Why?
|
| History, 20th Century | 1 | 1984 | 84 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2004 | 92 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 1998 | 1026 | 0.010 |
Why?
|
| Prodrugs | 1 | 2003 | 30 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2005 | 509 | 0.010 |
Why?
|
| Endothelial Protein C Receptor | 1 | 2003 | 7 | 0.010 |
Why?
|
| France | 1 | 2003 | 15 | 0.010 |
Why?
|
| Italy | 1 | 2003 | 14 | 0.010 |
Why?
|
| Liver Cirrhosis | 1 | 1984 | 74 | 0.010 |
Why?
|
| Solubility | 1 | 2003 | 73 | 0.010 |
Why?
|
| Antigens, CD7 | 1 | 2002 | 1 | 0.010 |
Why?
|
| Neprilysin | 1 | 2002 | 2 | 0.010 |
Why?
|
| Lymphocyte Subsets | 1 | 2002 | 8 | 0.010 |
Why?
|
| Dicumarol | 1 | 1982 | 1 | 0.010 |
Why?
|
| Thrombin Time | 1 | 1982 | 2 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2002 | 61 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 154 | 0.010 |
Why?
|
| Apolipoproteins B | 2 | 1993 | 18 | 0.010 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2002 | 59 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2004 | 461 | 0.010 |
Why?
|
| Health Status Indicators | 1 | 2002 | 25 | 0.010 |
Why?
|
| Fetal Tissue Transplantation | 1 | 2001 | 1 | 0.010 |
Why?
|
| Organ Culture Techniques | 1 | 2001 | 56 | 0.010 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2001 | 3 | 0.010 |
Why?
|
| Radiation Chimera | 1 | 2001 | 5 | 0.010 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2001 | 8 | 0.010 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2001 | 13 | 0.010 |
Why?
|
| CD5 Antigens | 1 | 2001 | 12 | 0.010 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 2001 | 12 | 0.010 |
Why?
|
| Genes, Immunoglobulin | 1 | 2001 | 10 | 0.010 |
Why?
|
| Graft Survival | 1 | 2001 | 29 | 0.010 |
Why?
|
| Platelet Count | 1 | 1982 | 111 | 0.010 |
Why?
|
| DNA Primers | 1 | 2001 | 147 | 0.010 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2002 | 64 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2002 | 210 | 0.010 |
Why?
|
| Prognosis | 1 | 2004 | 807 | 0.010 |
Why?
|
| Canada | 1 | 2001 | 60 | 0.010 |
Why?
|
| Obesity | 1 | 2007 | 675 | 0.010 |
Why?
|
| Liver Transplantation | 1 | 2001 | 56 | 0.010 |
Why?
|
| Models, Animal | 1 | 2001 | 130 | 0.010 |
Why?
|
| Bone Marrow | 1 | 2001 | 81 | 0.010 |
Why?
|
| Exercise Test | 1 | 2002 | 249 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2001 | 162 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2001 | 236 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2001 | 291 | 0.010 |
Why?
|
| Cellular Senescence | 1 | 2001 | 126 | 0.010 |
Why?
|
| Walking | 1 | 2002 | 135 | 0.010 |
Why?
|
| Survival Rate | 1 | 2001 | 431 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2000 | 31 | 0.010 |
Why?
|
| Outpatients | 1 | 2000 | 44 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1979 | 62 | 0.010 |
Why?
|
| False Negative Reactions | 1 | 1979 | 24 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1979 | 43 | 0.010 |
Why?
|
| Hip Joint | 1 | 1979 | 19 | 0.010 |
Why?
|
| Hip Fractures | 1 | 1979 | 10 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2001 | 667 | 0.010 |
Why?
|
| Inflammation | 1 | 2004 | 641 | 0.010 |
Why?
|
| Knee Joint | 1 | 1979 | 43 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2001 | 453 | 0.010 |
Why?
|
| Chemistry | 1 | 1979 | 10 | 0.010 |
Why?
|
| Chemical Phenomena | 1 | 1979 | 22 | 0.010 |
Why?
|
| Chromatography, Affinity | 1 | 1979 | 32 | 0.010 |
Why?
|
| Fibrinolysin | 1 | 1979 | 16 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2001 | 622 | 0.010 |
Why?
|
| Ischemia | 1 | 1999 | 83 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1979 | 169 | 0.010 |
Why?
|
| Thrombasthenia | 1 | 1998 | 1 | 0.010 |
Why?
|
| von Willebrand Diseases | 1 | 1998 | 4 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 1998 | 46 | 0.010 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1979 | 134 | 0.010 |
Why?
|
| Equipment Design | 1 | 1998 | 218 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 1996 | 38 | 0.010 |
Why?
|
| von Willebrand Factor | 1 | 1996 | 36 | 0.010 |
Why?
|
| Methods | 1 | 1995 | 27 | 0.010 |
Why?
|
| United States | 1 | 2001 | 2201 | 0.010 |
Why?
|
| Hematuria | 1 | 1994 | 10 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 1996 | 113 | 0.010 |
Why?
|
| Chemical Precipitation | 1 | 1993 | 6 | 0.010 |
Why?
|
| Cholesterol | 1 | 1993 | 202 | 0.010 |
Why?
|
| Genes, Recessive | 1 | 1991 | 21 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 1991 | 35 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1991 | 27 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1991 | 26 | 0.010 |
Why?
|
| Gene Amplification | 1 | 1991 | 22 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1991 | 128 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1991 | 270 | 0.010 |
Why?
|
| Alleles | 1 | 1991 | 354 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1991 | 1056 | 0.000 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1995 | 992 | 0.000 |
Why?
|
| Child, Preschool | 1 | 1991 | 1167 | 0.000 |
Why?
|
| Chromogenic Compounds | 1 | 1986 | 2 | 0.000 |
Why?
|
| Dipeptides | 1 | 1986 | 22 | 0.000 |
Why?
|
| Antigens | 1 | 1986 | 68 | 0.000 |
Why?
|
| Chronic Disease | 1 | 1986 | 273 | 0.000 |
Why?
|
| Surface Properties | 1 | 1984 | 134 | 0.000 |
Why?
|